Please login to the form below
PD-1/PD-L1 inhibitor
This page shows the latest PD-1/PD-L1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Merck shares positive late-stage results for Welireg in advanced kidney cancer
RCC that has progressed following PD-1/L1 checkpoint inhibitor and vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) therapies. ... Patients with advanced RCC face low survival rates, and for those whose cancer progresses following
Latest news
-
AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
Interim results from the phase 3 AEGEAN study, which is assessing the PD-1/L1 inhibitor in combination with neoadjuvant chemotherapy before surgery and as a monotherapy after surgery, showed the
-
AstraZeneca presents positive phase 3 results for Imfinzi regimen in lung cancer
Interim results from the AEGEAN study, which is assessing the PD-1/L1 inhibitor in combination with neoadjuvant chemotherapy before surgery and as a monotherapy after surgery, showed the regimen reduced ... Imfinzi is a human monoclonal antibody that
-
Gilead’s Trodelvy shows promise in phase 2 bladder cancer study
In cohort one, which assessed mUC patients whose cancer had progressed after platinum-based chemotherapy and checkpoint inhibitor therapy (CPI), Trodelvy was associated with a 10.9 months median overall survival, ... The drug has already received
-
Regeneron’s fianlimab/Libtayo combination shows positive results in advanced melanoma treatment
L1 inhibitor (PD-1/PD-L1-naïve) and one of patients who had received prior PD-1 or PD-L1 inhibitor therapy (PD-1/PD-L1-experienced). ... The objective response rate (ORR) in the PD-1/PD-L1-experienced cohort was 13%.
-
Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance
Bintrafusp alfa is part of a new wave of bispecific antibodies that are currently being developed by a number of companies as potential successors to the PD-1/PD-L1 inhibitor ... class. The molecule is designed to simultaneously target two
More from news
Approximately 1 fully matching, plus 64 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Mednet Group
PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
